Nat. Genet. 29, 143–152 (2001)
The annotation for the Affymetrix G110 probe set 1770 that we used was incorrect. Although the annotation specifies that the transcript for PDGFR-α is being ascertained, the true specificity of the probe set is for the PDGFR-β isoform. The ligand for both receptor isoforms is identical. The functional validation of the PDGFR signaling pathway, described in our article, used specific neutralizing antibodies against PDGFR-α as well as downstream small molecule inhibitors, and it implicates this entire cascade. The PDGFR-β isoform may be more relevant in the metastatic process, but this does not discount the proven biologic role of PDGFR-α and downstream effectors in metastatic medulloblastoma.
Additional information
The online version of the original article can be found at 10.1038/ng731
Rights and permissions
About this article
Cite this article
MacDonald, T., Brown, K., LaFleur, B. et al. Erratum: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 35, 287 (2003). https://doi.org/10.1038/ng1103-287a
Issue Date:
DOI: https://doi.org/10.1038/ng1103-287a
